Indications:
ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic
HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more prior regimens, including a trastuzumab-based regimen.
|